[Clinical study of a bufexamac-nystatin-neomycin combination in dermatology].
D002179:Candidiasis, Cutaneous / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004485:Eczema / Q000188:drug therapy; D005069:Evaluation Studies as Topic; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D007402:Intertrigo / Q000188:drug therapy; D009355:Neomycin / Q000627:therapeutic use*; D009761:Nystatin / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy*
D004338:Drug Combinations; D006877:Hydroxamic Acids; D009761:Nystatin; D009355:Neomycin
Contribution à l'etude clinique de l'association bufexamac-nystatine-neomycine en dermatologie.